Mitsubishi Tanabe's Key Products And M&A Rumors Tempered By Management Issues
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Mitsubishi Tanabe has industry observers scratching their heads. On one hand, the company has rights in Asia for telaprevir, a high-profile hepatitis C treatment, and its oral multiple sclerosis therapy Gilenya (fingolimod) recently gained approval in the U.S. through ex-Japan licensee Novartis and is on file for approval in Japan. But the company's repeated supply chain irregularities raise concern over management's ability to handle its manufacturing quality control process
You may also be interested in...
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
China's major players rack up double-digit growth in the second quarter, with WuXi PharmaTech celebrating its first $100 million quarter and Sinovac seeing a 50% increase in revenues. On the heels of the NovaMed acquisition, SciClone Pharmaceuticals Inc. is preparing to enter more markets in China and anticipates price cuts for its flagship product Zadaxin. In a recurring feature, PharmAsia News combs through earnings calls to bring readers the highlights in the critical emerging markets.
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
China's major players rack up double-digit growth in the second quarter, with WuXi PharmaTech celebrating its first $100 million quarter and Sinovac seeing a 50% increase in revenues. On the heels of the NovaMed acquisition, SciClone Pharmaceuticals Inc. is preparing to enter more markets in China and anticipates price cuts for its flagship product Zadaxin. In a recurring feature, PharmAsia News combs through earnings calls to bring readers the highlights in the critical emerging markets.
Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?
TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies